Evaluation of acquired resistance to temozolomide in a human glioma cell line
| Project/Area Number |
23791617
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Fujita Health University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | glioma / temozolomide / drug resistance / temodal / resistance / グリオーマ / テモゾロミド / 化学療法耐性 |
|---|
| Research Abstract |
In this study, we evaluated the mechanism of acquired temozolomide (TMZ) resistance in a human glioma cell line (U87MG). First, we generated a TMZ-resistant (TR) cell line. We then treated the TR cell line with TMZ and confirmed the suppression of G2 arrest and TMZ resistance using fluorescence-activated cell sorting analysis and a colony formation assay, respectively. Next, we examined the expression pattern of phosphorylated-cdc2 (Tyr15, Tyr161) to reveal the relationship between acquired resistance of TMZ and suppression of G2 arrest. Our results suggested that the TR cell line contains two types of cells: one that shows suppression of G2 arrest and another that shows transiently induced G2 arrest. Finally, we considered the relationship between genetic mutations in BRCA1 and acquired TMZ resistance. Western blotting analysis showed no significant difference in the expression of BRCA1 between the parental U87MG and TR cell lines.
|
Report
(4 results)
Research Products
(6 results)
